Canopy Growth (CGC) Income from Continuing Operations (2019 - 2025)

Canopy Growth (CGC) reported Income from Continuing Operations of 77577262.44 for Q4 2025, down 10.49% on a YoY basis from 86667892.64 in Q4 2024, and down 2044.68% sequentially from 3617189.04 in Q3 2025.

Canopy Growth (CGC) Income from Continuing Operations (2019 - 2025) Analysis & Trends

Canopy Growth (CGC) has 7 years of Income from Continuing Operations data on file, last reported at 77577262.44 in Q4 2025.

  • For the quarter ending Q4 2025, Income from Continuing Operations fell 10.49% year-over-year to 77577262.44; the trailing twelve-month figure through Dec 2025 stood at 183783827.17 (up 46.47% YoY), and the FY2026 full-year result was 191744636.7, down 173.54% from the prior year.
  • Income from Continuing Operations retreated to 77577262.44 in Q4 2025, from 3617189.04 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 317238982.72 in Q2 2021 to a low of 1640644562.36 in Q2 2022.
  • A 5-year average of 147661271.75 and a median of 82263253.69 in 2024 frame the typical range for Income from Continuing Operations.
  • Across the five-year window, Income from Continuing Operations soared 442.79% in 2021 and tumbled 1061.13% in 2022, its largest moves.
  • Tracing CGC's Income from Continuing Operations over 5 years: stood at 91627144.08 in 2021, then tumbled by 82.39% to 167116641.72 in 2022, then rose by 3.68% to 160968319.01 in 2023, then soared by 56.38% to 70212631.25 in 2024, then decreased by 10.49% to 77577262.44 in 2025.
  • Business Quant data shows CGC's Income from Continuing Operations at 77577262.44 in Q4 2025, 3617189.04 in Q3 2025, and 32376744.43 in Q2 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Income (Continuing) (Qtr)
1 Haleon 87.22 Bn 85.35 Bn - -
2 Teva Pharmaceutical Industries 39.60 Bn 35.87 Bn 1.97 Bn 370.00 Mn
3 Zoetis 31.46 Bn 29.52 Bn 1.62 Bn 601.00 Mn
4 Takeda Pharmaceutical 26.49 Bn 22.44 Bn 4.39 Bn -3.58 Bn
5 United Therapeutics 23.03 Bn 20.88 Bn 648.10 Mn 274.90 Mn
6 Universe Pharmaceuticals 23.03 Bn -10.56 Bn - -
7 Viatris 20.90 Bn 19.09 Bn 1.16 Bn 176.40 Mn
8 Neurocrine Biosciences 17.50 Bn 16.19 Bn 800.70 Mn 197.90 Mn
9 Elanco Animal Health 12.33 Bn 11.91 Bn 785.00 Mn 57.00 Mn
10 Canopy Growth 197.77 Mn -68.15 Mn - -

Historic Data

Download Data
DateValue
Dec 31, 2025 -77.58 Mn
Sep 30, 2025 -3.62 Mn
Jun 30, 2025 -32.38 Mn
Dec 31, 2024 -70.21 Mn
Sep 30, 2024 -82.26 Mn
Jun 30, 2024 -78.91 Mn
Mar 31, 2024 -111.94 Mn
Dec 31, 2023 -160.97 Mn
Sep 30, 2023 -104.09 Mn
Jun 30, 2023 -7.87 Mn
Mar 31, 2023 165.78 Mn
Dec 31, 2022 -167.12 Mn
Sep 30, 2022 -150.64 Mn
Jun 30, 2022 -1.64 Bn
Mar 31, 2022 -408.19 Mn
Dec 31, 2021 -91.63 Mn
Sep 30, 2021 -12.97 Mn
Jun 30, 2021 317.24 Mn
Mar 31, 2021 -87.57 Mn
Dec 31, 2020 -636.08 Mn